iHD38Q-2
ICGi018-B
General
Cell Line |
|
| hPSCreg name | ICGi018-B |
| Cite as: | ICGi018-B (RRID:CVCL_YK94) |
| Alternative name(s) |
iHD38Q-2
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
RCi004-A-1 (RCi004-A + HTT GC #H34-32_T34-23) Donor's gene variants: HTT Donor diseases: Huntington disease |
| Last update | 14th April 2022 |
| User feedback | |
Provider |
|
| Generator | Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (ICG) |
| Owner | Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (ICG) |
| Distributors | |
| Derivation country | Russia |
External Databases |
|
| BioSamples | SAMEA6438550 |
| Cellosaurus | CVCL_YK94 |
| Wikidata | Q94313469 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Cell line can only be used in: Study of the Huntington's disease pathology mechanims
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | female |
| Age of donor (at collection) | 80-84 |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
Genetic variants
HTT (target) 4p16.3
Heterozygous
The patient has 18/38 CAG repeats in the HTT gene exon 1.
The mutation of CAG triplet expansion in the HTT gene was detected by capillary electrophoresis. It was performed using capillary genetic analyzer ABI Prism 3130 (Applied Biosystems), size standard Liz 600; obtained data were analyzed using Data Collection software v3.0 and GeneMapper v. 4.0 (Applied Biosystems).
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA6438238 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | No |
| a non-profit company? | No |
| a for-profit corporation? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | Yes |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | Yes |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Research Center of Neurology |
| Approval number | 10/12 15.08.12 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Research Center of Neurology |
| Approval number | 10/12 15.08.12 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
hIPSC Derivation
General |
|
| Source cell type |
Synonyms
|
| Source cell origin |
Synonyms
|
| Age of donor (at collection) | 80-84 |
| Collected in | 2018 |
| Passage number reprogrammed | 1 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | morphology |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Gelatin | ||||||||||||||||||
| Feeder cells |
Mouse embryonic fibroblasts |
||||||||||||||||||
| Passage method |
Enzymatically
TrypLE
|
||||||||||||||||||
| O2 Concentration | 20 % | ||||||||||||||||||
| CO2 Concentration | 5 % | ||||||||||||||||||
| Medium |
Other medium:
Base medium: Knock-out DMEM
Main protein source: Knock-out serum replacement Serum concentration: 15 % Supplements
|
||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| Alkaline Phosphatase |
Yes |
|||||
| SOX2 |
Yes |
|||||
| TRA 1-60 |
Yes |
|||||
| SSEA-4 |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
Score:
| Marker | Present | Absent |
| mCpG | ||
| OCT4 |
Morphology pictures
Differentiation Potency
In vitro spontaneous differentiation
| Marker | Expressed |
| TBX3 |
Yes |
| Hepatocyte nuclear factor 3-beta |
Yes |
Morphology
In vitro spontaneous differentiation
| Marker | Expressed |
| Neurofilament 200 |
Yes |
| Tubulin, beta 3 |
Yes |
Morphology
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.